U.S. Markets closed

Why This Migraine-Focused Biotech Stock Could Be The Next Takeover

ALLISON GATLIN
Why This Migraine-Focused Biotech Stock Could Be The Next Takeover

Alder Biopharmaceuticals could be an acquisition target, an analyst said Tuesday after the Food and Drug Administration accepted its application for a migraine-prevention treatment.